VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AREAlexandria Real Estate Equities, Inc.
$55.22$9.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAREBalance Sheet

Alexandria Real Estate Equities, Inc. (ARE) Balance Sheet

30Y historyFree accessUpdated daily

The company's financial leverage has trended upward, with the debt-to-equity ratio climbing from 0.52 in 2023Q4 to 0.65 in 2026Q1, alongside a reduction in total assets to $34.2 billion.

ARE Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Assets34.17B34.08B37.53B36.77B35.52B30.22B22.83B18.39B14.46B12.1B10.35B8.91B8.14B7.53B7.15B6.57B5.91B5.46B5.13B4.64B3.62B2.36B1.87B1.27B1.16B962.15M780.98M643.1M530.3M248.5M160.4M
Asset Growth %-21.8%-9.18%2.06%3.51%17.55%32.38%24.13%27.14%19.51%16.89%16.2%9.53%8.05%5.31%8.76%11.32%8.22%6.36%10.53%28.32%53.12%26.18%47.13%9.78%20.49%23.2%21.44%21.27%113.4%54.93%-
Real Estate & Other Assets3.4B30.51B33.67B32.89B30.93B25.73B19.17B15.82B12.76B11.01B9.66B8.16B7.57B7.29B6.85B360.56M-5.44B-5.04B-4.72B-4.29B-3.32B-2.12B-1.68B-1.14B-1.04B-861.88M-705.75M-598.8M-493.7M-230M-147M
PP&E (Net)28.83B1.1B1.25B1.15B1.35B1.26B982.99M743.68M228.72M108.12M96.14M41.68M28.83M006.01B5.44B5.04B4.72B4.29B3.32B2.12B1.68B1.14B1.04B861.88M705.75M598.8M493.7M230M147M
Investment Securities1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K000000000000000
Total Current Assets430.75M939.78M783.64M781.75M973.91M707.23M727.83M336.08M348.27M347.99M202.13M202.45M180.2M95.32M189.37M109.35M000000000000000
Cash & Equivalents418.72M549.06M552.15M618.19M825.19M361.35M568.53M189.68M234.18M254.38M125.03M125.1M86.01M57.7M140.97M78.54M91.23M70.63M71.16M8.03M2.95M3.91M3.16M4.99M3.79M2.38M2.78M3.4M1.6M2.1M1.7M
Receivables1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Assets4.67M4.69M7.7M42.58M32.78M53.88M29.17M53.01M37.95M22.8M16.33M28.87M26.88M27.71M39.95M23.33M-96.72M-74.53M-77.61M-14.79M-9.28M-8.68M-5.7M-6.95M-6.43M-11.5M-11.61M-12.8M-10.5M-5.7M-2.9M
Intangible Assets00305.14M461.61M615.64M609.87M0000000000000000000000000
Total Liabilities14.81B14.93B15.13B14.15B12.84B11.19B9.38B8.22B6.57B5.62B4.97B4.62B4.23B3.55B3.65B3.14B2.92B3.09B3.39B3.06B2.21B1.51B1.25B765.44M673.39M629.51M461.83M380.5M330.5M81.6M120.8M
Total Debt12.52B12.76B12.75B11.7B10.57B9.23B7.91B7.05B5.48B4.85B4.22B3.96B3.69B3.07B3.2B2.8B2.58B2.75B2.94B2.79B2.02B1.41B1.19B709.01M614.88M573.16M431.26M350.5M309.8M70.8M113.2M
Net Debt12.1B12.21B12.2B11.08B9.74B8.87B7.34B6.86B5.24B4.6B4.1B3.84B3.6B3.01B3.06B2.72B2.49B2.68B2.87B2.78B2.02B1.4B1.18B704.02M611.09M570.78M428.48M347.1M308.2M68.7M111.5M
Long-Term Debt11.17B12.05B12.24B11.22B10.16B8.52B7.46B6.39B5.27B4.71B4.14B3.78B3.37B2.86B2.62B2.41B2.58B2.75B2.94B2.79B2.02B1.41B1.19B709.01M614.88M573.16M427.37M350.5M309.8M70.8M113.2M
Short-Term Borrowings1.35B353.16M099.95M0269.99M99.99M384M208M50M28M151M304M204M566M370M00000000003.88M0000
Capital Lease Obligations1.09B360.54M507.13M382.88M406.7M434.75M345.75M271.81M088.18M59.51M26.02M8.81M11.4M14.72M17.92M000000000000000
Total Current Liabilities3.64B2.18B1.96B2B1.67B1.73B1.15B1.26B1.06B740.95M702.5M664.45M775.45M622.8M939.9M633.5M000000000000000
Accounts Payable2.15B510.58M534.8M524.44M389.74M513.42M285.02M198.99M215.54M349.88M366.17M239.84M218.94M98.04M105.52M86.42M000000000000000
Deferred Revenue0876.25M691.87M548.53M449.62M326.92M276.75M275.86M250.92M248.92M231.42M211.6M193.7M188.24M143.88M103.49M000000000000000
Other Liabilities0334.86M419.66M548.76M600.76M496.46M152.29M21.92M-11.56M-172.08M-156.84M-99.71M-126.06M-128.68M-67.39M-22.93M-2.58B-2.75B-2.94B-2.79B-2.02B-1.41B-1.19B-709.01M-614.88M-573.16M-427.37M-350.5M-309.8M-70.8M-113.2M
Total Equity19.35B19.16B22.4B22.62B22.68B19.03B13.44B10.17B7.89B6.48B5.38B4.29B3.91B3.98B3.5B3.43B2.99B2.36B1.75B1.58B1.41B849.91M620.47M507.13M485.85M332.64M319.15M262.6M199.8M166.9M39.6M
Equity Growth %-37.57%-14.47%-0.99%-0.27%19.18%41.58%32.24%28.78%21.77%20.45%25.35%9.83%-1.74%13.58%2.04%14.95%26.29%35.49%10.5%12.08%65.8%36.98%22.35%4.38%46.06%4.23%21.54%31.43%19.71%321.46%-
Shareholders Equity15.73B15.47B17.89B18.47B18.97B16.19B11.73B8.87B7.34B5.95B4.9B3.98B3.83B3.92B3.44B3.37B2.93B2.32B1.7B1.5B1.35B829.8M620.47M507.13M485.85M332.64M319.15M262.6M199.8M166.9M39.6M
Minority Interest3.62B3.69B4.51B4.15B3.71B2.84B1.72B1.3B552.75M533.5M486.48M318.88M81.12M62.15M61.21M58.59M57.5M82.67M41.09M75.51M57.48M20.11M000000000
Common Stock1.71M1.71M1.72M1.72M1.71M1.58M1.37M1.21M1.11M998K877K725K715K712K632K616K550K438K319K316K290K224K196K193K190K163K155K100K100K00
Additional Paid-in Capital15.76B15.5B17.93B18.49B18.99B16.2B11.73B8.87B7.29B5.82B4.67B3.56B3.46B3.57B3.09B3.03B2.57B1.98B1.41B1.37B1.14B607.4M421.83M409.93M399.83M301.82M278.87M225.2M199.6M173.7M16.2M
Retained Earnings0000000000000000734K000005.27M8.63M00000-6.9M-1.8M
Preferred Stock0000000064.34M74.39M216.91M367.16M367.16M380M380M379.64M379.64M379.64M379.64M129.64M187.14M187.14M187.14M96.09M96.09M38.59M38.59M38.6M0025.2M
Return on Assets (ROA)-2.86%-4%0.87%0.29%1.59%2.15%3.74%2.21%3.89%1.51%-0.68%1.69%1.3%1.86%1.49%2.11%2.38%2.54%2.38%2.27%2.46%3%3.83%4.91%3.77%3.47%3.65%3.77%4.98%-1.37%1.37%
Return on Equity (ROE)-5.03%-6.88%1.43%0.46%2.5%3.52%6.53%4.02%7.2%2.85%-1.36%3.52%2.58%3.64%2.94%4.09%5.06%6.55%7%6.27%6.5%8.63%10.68%12.01%9.78%9.29%8.94%9.56%10.58%-2.71%5.56%
Debt / Assets36.64%37.44%33.98%31.81%29.75%30.53%34.65%38.33%37.87%40.09%40.79%44.46%45.32%40.8%44.71%42.55%43.76%50.34%57.26%60.06%55.97%59.54%63.4%55.71%53.04%59.57%55.22%54.5%58.42%28.49%70.57%
Debt / Equity0.65x0.67x0.57x0.52x0.47x0.48x0.59x0.69x0.69x0.75x0.78x0.92x0.94x0.77x0.91x0.81x0.87x1.16x1.68x1.77x1.44x1.66x1.91x1.40x1.27x1.72x1.35x1.33x1.55x0.42x2.86x
Net Debt / EBITDA162.89x82.40x6.19x6.21x6.03x6.65x3.92x7.13x3.85x4.30x5.88x9.64x8.89x9.42x10.45x7.72x7.52x8.04x9.25x10.02x9.09x8.08x8.86x5.55x6.04x6.28x5.58x5.72x7.05x7.55x10.23x
Book Value per Share102.74112.42130.17132.37140.32129.07106.2890.3576.4170.4270.7260.0354.9358.4856.3658.1161.6961.2754.7052.6455.3139.8930.3826.3527.2020.5221.7119.2116.2420.6710.87

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Capital structure leverage sensitivity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Contraction and Deleveraging

As reported in recent financial statements, total assets declined from $38.5 billion in 2024Q3 to $34.2 billion in 2026Q1, reflecting a strategic pivot toward asset base reduction that suggests management is actively shrinking the portfolio to navigate current market volatility and capital constraints.

The reduction in total assets, coupled with a simultaneous decrease in total debt from $14.0 billion to $12.5 billion over the same period, indicates a deliberate effort to deleverage the balance sheet. This contraction appears to be a defensive response to the challenging interest rate environment and the need to preserve capital amid a cooling biotech funding cycle.

Debt-to-Equity Ratio Trends Upward

Based on the company's reported figures, the debt-to-equity ratio has climbed from 0.52 in 2023Q4 to 0.65 in 2026Q1, signaling that the firm's reliance on debt financing has increased relative to its equity base despite recent efforts to manage total debt levels.

The upward trend in the debt-to-equity ratio suggests that the firm's equity base has eroded faster than its debt obligations, likely due to the non-cash impairment charges noted in previous periods. Investors should monitor whether this leverage profile limits the company's capacity to fund its remaining development pipeline without further dilutive equity issuance.

Cash Reserves Under Sustained Pressure

According to quarterly filings, cash balances have fluctuated significantly, dropping from a peak of $722.2 million in 2024Q1 to $418.7 million in 2026Q1, which highlights the ongoing liquidity strain caused by high capital expenditure requirements for specialized lab infrastructure maintenance.

The decline in cash reserves suggests that the company is consuming liquidity to support its operations and development commitments during a period of revenue contraction. This tightening liquidity position may reduce the firm's flexibility to pursue opportunistic acquisitions or respond to unforeseen capital needs within its cluster portfolio.

Hidden Risks in Asset Valuation

As evidenced by the volatility in net property, plant, and equipment figures, which plummeted from $1.3 billion in 2024Q4 to $1.1 billion in 2025Q4, there is a clear indication that the firm is aggressively writing down the carrying value of its aging lab assets.

This rapid adjustment in net PPE suggests that the book value of the portfolio may be subject to further downward revisions if market capitalization rates continue to expand. The discrepancy between historical cost and current market value warrants investigation into whether the firm's remaining assets are adequately positioned for long-term competitive viability.

ARE — Frequently Asked Questions

Quick answers to the most common questions about buying ARE stock.

What are the total assets of Alexandria Real Estate Equities, Inc. (ARE)?

As of 2025, Alexandria Real Estate Equities, Inc. (ARE) had total assets of $34.08B including $939.8M in current assets.

How much debt does Alexandria Real Estate Equities, Inc. (ARE) have?

Alexandria Real Estate Equities, Inc. (ARE) carries total debt of $12.76B. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Alexandria Real Estate Equities, Inc.?

Alexandria Real Estate Equities, Inc. (ARE) has total shareholders' equity (book value) of $15.47B ($112.42 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Alexandria Real Estate Equities, Inc.'s current ratio and liquidity?

Alexandria Real Estate Equities, Inc. (ARE) reported a current ratio of 0.43x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.